Trial Profile

A Phase II clinical proof-of-concept study of fimaVacc

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fimaporfin delivered cancer vaccine-PCI Biotech (Primary)
Indications Head and neck cancer
Focus Proof of concept; Therapeutic Use
Sponsors PCI Biotech

Most Recent Events

18 Aug 2022 According to a PCI Biotech media release, PCI Biotech will not conduct the trial because previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward.
18 Aug 2022 Status changed from planning to discontinued, according to a PCI Biotech media release.
11 May 2022 According to a PCI Biotech media release, the manufacturing and sourcing of study treatments for this study is underway, and selection of clinical sites has started.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com